Screening Protocol To Determine Eligibility For Studies Of The Chemokine Coreceptor 5 (CCR5) Antagonist GW873140

This study has been terminated.
(The study was terminated due to hepatoxicity of compound)
Sponsor:
Information provided by:
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00123890
First received: July 22, 2005
Last updated: March 28, 2011
Last verified: March 2011
  Purpose

The purpose of this study is to determine eligibility for one of three treatment studies of the CCR5 antagonist GW873140 or an observational study without GW873140. No investigational treatment will be administered through this study.


Condition Intervention Phase
HIV Infection
Drug: GW873140
Phase 3

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: A Screening Protocol to Determine Eligibility for One of Three Phase III Treatment Studies Evaluating the Efficacy and Safety of GW873140 in R5-tropic and R5/X4-tropic HIV-1 Infected, Treatment-experienced Subjects With Drug-resistant Virus or an Observational Study.

Resource links provided by NLM:


Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Determination of subject eligibility for CCR102709, CCR104456, CCR104458, or CCR104629. [ Designated as safety issue: Yes ]

Enrollment: 0
Study Start Date: June 2005
Study Completion Date: October 2005
Primary Completion Date: October 2005 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: GW873140
    Other Name: GW873140
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • HIV-infected.
  • Screening viral load at least 5000copies/mL.
  • Total prior antiretroviral experience of at least 3 months and documented resistance to at least one drug in each of the following classes: nucleoside reverse transcriptase inhibitors (NRTI), non-nucleoside reverse transcriptase inhibitors (NNRTI), and protease inhibitors (PI), stable antiretroviral regimen (or no antiretroviral treatment) for at least 4 weeks before screening.
  • Able to receive a ritonavir-boosted protease inhibitor during treatment studies.
  • Women of childbearing potential must use specific forms of contraception.

Exclusion criteria:

  • Acute laboratory abnormalities.
  • History of pancreatitis or hepatitis, hepatitis B or hepatitis C coinfection, or any chronic liver disease. Screening liver function tests will be used to determine eligibility.
  • Changes to antiretroviral therapy from 4 weeks prior to screening until Day 1 of treatment or observational studies.
  • Pregnancy or breastfeeding women.
  • Recent participation in an experimental drug trial.
  • Prior use of a CCR5 or CXCR4 antagonist.
  • Significant ECG abnormalities or significant history of active pancreatitis, hepatitis, opportunistic infections, malabsorption disorders, cancer, or severe illness.
  • Current use of certain medications may exclude participation in this study.
  • Additional qualifying criteria and laboratory test requirements to be assessed by study physician.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00123890

  Hide Study Locations
Locations
United States, Arizona
GSK Investigational Site
Tucson, Arizona, United States, 85745
United States, California
GSK Investigational Site
Laguna Beach, California, United States, 92651
GSK Investigational Site
Long Beach, California, United States, 90813
GSK Investigational Site
Los Angeles, California, United States, 90046
GSK Investigational Site
Oakland, California, United States, 94609
GSK Investigational Site
Tarzana, California, United States, 30342
United States, Connecticut
GSK Investigational Site
Glastonbury, Connecticut, United States, 06033
GSK Investigational Site
Norwalk, Connecticut, United States, 06851
United States, District of Columbia
GSK Investigational Site
Washington, District of Columbia, United States, 20009
United States, Florida
GSK Investigational Site
Fort Lauderdale, Florida, United States, 33308
GSK Investigational Site
Hollywood, Florida, United States, 33020
GSK Investigational Site
Oakland Park, Florida, United States, 33334
GSK Investigational Site
Orlando, Florida, United States, 32804
GSK Investigational Site
Plantation, Florida, United States, 33317
GSK Investigational Site
Tampa, Florida, United States, 33607
United States, Georgia
GSK Investigational Site
Atlanta, Georgia, United States, 30339
United States, Illinois
GSK Investigational Site
Chicago, Illinois, United States, 60657
United States, Louisiana
GSK Investigational Site
New Orleans, Louisiana, United States, 70127-0800
United States, Maryland
GSK Investigational Site
Baltimore, Maryland, United States, 21201
United States, Massachusetts
GSK Investigational Site
Boston, Massachusetts, United States, 02215
United States, Minnesota
GSK Investigational Site
Minneapolis, Minnesota, United States, 55404
United States, Nevada
GSK Investigational Site
Las Vegas, Nevada, United States, 89102
United States, New Jersey
GSK Investigational Site
East Orange, New Jersey, United States, 07018
GSK Investigational Site
Newark, New Jersey, United States, 07102
United States, New York
GSK Investigational Site
New York, New York, United States, 10014
United States, Ohio
GSK Investigational Site
Akron, Ohio, United States, 44304
United States, Oregon
GSK Investigational Site
Portland, Oregon, United States, 97219
GSK Investigational Site
Portland, Oregon, United States, 97209
United States, Texas
GSK Investigational Site
Austin, Texas, United States, 78746
GSK Investigational Site
Dallas, Texas, United States, 75246
GSK Investigational Site
Houston, Texas, United States, 77027
United States, Virginia
GSK Investigational Site
Hampton, Virginia, United States, 23666
GSK Investigational Site
Lynchburg, Virginia, United States, 24501
United States, Washington
GSK Investigational Site
Spokane, Washington, United States, 99204
Belgium
GSK Investigational Site
Bruxelles, Belgium, 1000
GSK Investigational Site
Charleroi, Belgium, 6000
Canada, Ontario
GSK Investigational Site
Toronto, Ontario, Canada, M5B 1L6
Denmark
GSK Investigational Site
Koebenhavn, Denmark, DK-2100
Germany
GSK Investigational Site
Hannover, Niedersachsen, Germany, 30625
GSK Investigational Site
Duesseldorf, Nordrhein-Westfalen, Germany, 40225
GSK Investigational Site
Koeln, Nordrhein-Westfalen, Germany, 50937
GSK Investigational Site
Hamburg, Germany, 20099
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials, Ph.D. GlaxoSmithKline
  More Information

No publications provided

Responsible Party: Study Director, GSK
ClinicalTrials.gov Identifier: NCT00123890     History of Changes
Other Study ID Numbers: CCR104627
Study First Received: July 22, 2005
Last Updated: March 28, 2011
Health Authority: United States: Food and Drug Administration
Denmark: Danish Medicines Agency
Belgium: Ministry of Social Affairs, Public Health and the Environment

Keywords provided by GlaxoSmithKline:
HIV-1 GW873140 CCR5 antagonist experienced

Additional relevant MeSH terms:
HIV Infections
Acquired Immunodeficiency Syndrome
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Slow Virus Diseases

ClinicalTrials.gov processed this record on July 20, 2014